Apoptosis is a morphologically and biochemically distinct form of cell death that has been observed during development, after withdrawal of trophic hormones or treatment with chemotherapeutic agents, and during the course of cell-mediated immunotoxicity. The present proposal seek funds for collaborative studies by two laboratories with a long-standing interest in the mechanism of chemotherapy-induced apoptosis. Previous studies from these laboratories have demonstrated that l) topoisomerase- directed agents and a variety of other clinically useful antineoplastic agents induce apoptosis in a variety of cell types, 2) the morphologic changes of apoptosis are accompanied by the early, quantitative cleavage of a number of nuclear proteins including poly(ADP-ribose polymerase) and the nuclear lamins, and 3) the morphological and biochemical events of apoptosis can be recapitulated with synchrony and high fidelity in a unique cell-free assay developed using the cytosol from cells committed to apoptosis. Using this cell-free system, we have more recently identified two distinct protease activities that appear to play pivotal roles during the course of apoptosis. One, termed priCE (protease resembling interleukin-1-beta converting enzyme), cleaves the nuclear enzyme poly(ADP-ribose) polymerase prior to the earliest detectable cleavage of DNA into nucleosomal fragments. Inhibitors of priCE prevent all of the morphological and biochemical events associated with apoptosis (including cleavage of protein and DNA), suggesting that activation of priCE occurs very early in the process of apoptosis. A second protease with a distinct inhibitor profile is responsible for lamin degradation that occurs later in apoptosis and is required for the nuclear reorganization that results in apoptotic bodies. We now propose a series of experiments designed to characterize these proteases, investigate their structure and regulation, and further evaluate their role in controlling apoptosis. in particular, we propose to l) clone the cDNA for priCE using one of three different strategies, 2) utilize a novel fluorogenic assay and immunological probes against priCE to study the regulation of priCE in tissue culture cells and clinical tumor specimens that differ in their intrinsic ability to undergo apoptosis, 3) identify additional priCE substrates, 4) characterize in greater detail the lamin protease, and 5) isolate and characterize a recently demonstrated naturally-occurring inhibitor of apoptosis. These studies should provide insight into the structure and regulation of biochemical activities that appear to play a pivotal role in the control of chemotherapy-induced cell death.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069008-03
Application #
2390902
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1995-04-01
Project End
1998-03-31
Budget Start
1997-04-01
Budget End
1998-03-31
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Zhang, J-S; Herreros-Villanueva, M; Herreros-Vilanueva, M et al. (2014) Differential activity of GSK-3 isoforms regulates NF-?B and TRAIL- or TNF? induced apoptosis in pancreatic cancer cells. Cell Death Dis 5:e1142
Lee, S-H; Meng, X W; Flatten, K S et al. (2013) Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ 20:64-76
Gores, Gregory J; Kaufmann, Scott H (2012) Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 26:305-11
Gupta, Mamta; Hendrickson, Andrea E Wahner; Yun, Seong Seok et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119:476-87
Pang, Yuan-Ping; Dai, Haiming; Smith, Alyson et al. (2012) Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization. Sci Rep 2:257
Dai, Haiming; Smith, Alyson; Meng, X Wei et al. (2011) Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol 194:39-48
Ding, Husheng; Hackbarth, Jennifer; Schneider, Paula A et al. (2011) Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood 118:4872-81
Smith, Alyson J; Dai, Haiming; Correia, Cristina et al. (2011) Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 286:17682-92
Schnepple, David J; Shepard, Brett; Bren, Gary D et al. (2011) Isolation of a TRAIL antagonist from the serum of HIV-infected patients. J Biol Chem 286:35742-54
Meng, Xue Wei; Peterson, Kevin L; Dai, Haiming et al. (2011) High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem 286:35823-33

Showing the most recent 10 out of 84 publications